摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-(3,5-dimethyl-2,4'-bipyridin-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one | 1373615-61-2

中文名称
——
中文别名
——
英文名称
1-(4-(3,5-dimethyl-2,4'-bipyridin-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one
英文别名
1-[4-[4-(3,5-dimethylpyridin-2-yl)pyridin-2-yl]piperazin-1-yl]-3-methylsulfonylpropan-1-one
1-(4-(3,5-dimethyl-2,4'-bipyridin-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one化学式
CAS
1373615-61-2
化学式
C20H26N4O3S
mdl
——
分子量
402.517
InChiKey
RZOKTVMRGRINNO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    28
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    91.8
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Pyridine-2-derivatives as smoothened receptor modulators
    申请人:Nair Sajiv Krishnan
    公开号:US09056865B2
    公开(公告)日:2015-06-16
    The present application relates to compounds of Formula (I), and Formula (II), or pharmaceutically acceptable salt thereof, wherein A, X, Y, Z, e, f, R1, R2, R3, R4, R5, R5b, R6, R7, R8, R9, R10, R11, R20, R21, R22 and R23 are defined herein. These novel pyridine derivatives that are useful in therapy, in particular for treating diseases or conditions mediated by Smo, including the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to methods of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    本申请涉及式(I)和式(II)的化合物,或其药学上可接受的盐,其中A、X、Y、Z、e、f、R1、R2、R3、R4、R5、R5b、R6、R7、R8、R9、R10、R11、R20、R21、R22和R23在此定义。这些新型吡啶衍生物在治疗中有用,特别用于治疗由Smo介导的疾病或病况,包括治疗哺乳动物中的异常细胞生长,如癌症。其他实施例涉及使用这些化合物治疗哺乳动物,特别是人类的异常细胞生长的方法,以及含有这些化合物的制药组合物。
  • PYRIDINE-2-DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS
    申请人:Nair Sajiv Krishnan
    公开号:US20130210800A1
    公开(公告)日:2013-08-15
    The present application relates to compounds of Formula (I), and Formula (II), or pharmaceutically acceptable salt thereof, wherein A, X, Y, Z, e, f, R 1 , R 2 , R 3 , R 4 , R 5 , R 5b , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 20 , R 21 , R 22 and R 23 are defined herein. These novel pyridine derivatives that are useful in therapy, in particular for treating diseases or conditions mediated by Smo, including the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to methods of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    本申请涉及式(I)和式(II)的化合物,或其药学上可接受的盐,其中A、X、Y、Z、e、f、R1、R2、R3、R4、R5、R5b、R6、R7、R8、R9、R10、R11、R20、R21、R22和R23在此被定义。这些新型吡啶衍生物在治疗中有用,特别是用于治疗由Smo介导的疾病或病况,包括治疗哺乳动物中的异常细胞生长,如癌症。其他实施例涉及使用这些化合物治疗哺乳动物,特别是人类中的异常细胞生长的方法,以及包含这些化合物的制药组合物。
  • PYRIDINE- 2- DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS
    申请人:Pfizer Inc.
    公开号:EP2630134A1
    公开(公告)日:2013-08-28
  • PYRIDINE-2- DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS
    申请人:Pfizer Inc.
    公开号:EP2630134B1
    公开(公告)日:2015-05-20
  • US9056865B2
    申请人:——
    公开号:US9056865B2
    公开(公告)日:2015-06-16
查看更多